Drug profile

The FDA adverse-event record for Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv

Name: Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

10 FDA reports name Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2574 of 2,679
by report volume (all drugs): 10
adverse-event reports: 20.0%
death-coded share: Horse
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv ranks #2536 of 2679 by total reports (10). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #2536
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Signature read: 10 reports place Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv in the lower third of FDA AER volume (#2574 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

20.0%

Death-coded share of reports

Active Ingredients

Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv

Administration Routes

IntramuscularUnknown

Species Affected

Horse 10

Most Affected Breeds

Thoroughbred 2

Warmblood (unspecified) 2

Quarter Horse 1

Crossbred Equine/horse 1

Miniature 1

Lusitano 1

Morgan 1

Horse (other) 1

Most Reported Reactions

Fever 4

Injection site swelling 4

Nasal discharge 2

Injection site pain 2

Injection site lump 2

Breathing difficulty 1

Lung sound 1

Hives (see also 'Skin') 1

Lethargy (see also Central nervous system depression in 'Neurological') 1

Injection site hair loss 1

Injection site skin discolouration 1

Injection site weeping (see also 'skin') 1

Outcome Breakdown

Ongoing

5 (50.0%)

Recovered/Normal

3 (30.0%)

Died

1 (10.0%)

Euthanized

1 (10.0%)

Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Eiv*3/W,Eev/Ehv1,4/Tet/Yf-Wnv (#2574 of 2,679 by report volume); death-coded 20.0%. PlainBreed drug row · report volume stamp 10 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →